Answers are grounded in this paper and cite their sources.
Explores enhanced mobilization of hematopoietic stem cells for blood malignancies, indicating improved safety and outcomes.
Revolutionising hematopoietic stem cell mobilisation An innovative strategy for hematopoietic stem cell mobilisation for transplantation is using a combination of CXCR4 and VLA-4 inhibitors to improve efficiency, safety, and outcomes in blood-related therapies. Hematopoietic stem cell transplantation (HSCT) is essential for treating a variety of blood malignancies and disorders, including gene therapy of sickle cell anemia. A key step in this procedure is the mobilisation of a significant number of primitive hematopoietic stem cells (HSCs) from the bone marrow to the peripheral blood to ensure rapid, durable engraftment after autologous or allogeneic transplantation. Because current HSC mobilisation regimens have limitations, a safer, faster, and more cost-effective approach is needed to improve outcomes and shorten treatment timelines. HSCs and their clinical applications. As the foundation of the blood system, HSCs reside primarily in the bone marrow, providing lifelong, self-renewing differentiation into all blood lineages. Mobilising these cells into the peripheral blood for harvesting is critical to clinical practice, enabling HSCT for various blood malignancies (Fig. 1). Beyond traditional transplant, these mobilised HSCs are increasingly used for gene editing strategies to treat genetic blood disorders such as sickle cell anemia and beta-thalassemia. Advancing curative HSCT and gene-editing therapies requires infusing a sufficient quantity of HSCs, which then must home back to the bone marrow to establish durable lifelong blood production.
No takes yet. Share an insight, caveat, or question.
DiPersio et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: